Partners
Partners

Partner 22 - Gilupi


Alexander Herrmann

 

CEO

 


 

 

 

GILUPi

 

Hermannswerder 20a

14473 Potsdam

Germany

 

undefinedWebsite

CANCER-ID Team GILUPI

Dr. Claudia Chudak

 

Marketing and Sales

Application Specialist

 

Phone: +49 331-58184785

undefinedE-mail

 


 

 


 

Institute presentation

 

GILUPI is a specialized medical technology company focused on the development and production of the GILUPI CellCollector™ technology, a medical device used in the upstream value chain of molecular diagnostics.

GILUPI has developed a unique and proprietary technology platform that represents a major improvement in the harvesting of rare cells, such as circulating tumour cells (“CTCs”) or circulating endothelial cells (“CECs”), directly in the patient’s blood stream. Current state of the art diagnostic analyses are based on limited volumes of blood samples and subsequent in vitro enumeration and characterization. In contrast to these methodologies, the GILUPI technology isolates the cells in vivo with high sensitivity and selectivity providing compelling and improved diagnostic value.

Application of the GILUPI technology renders living cells that today can only be harvested in sufficient numbers via biopsies. But biopsies are invasive and thus are associated with risk for the patient and are often even not available due to a lack of localized appropriate tissue (e.g. after surgery of the primary tumour or in general due to the disease e.g. in cardiovascular diseases). The advanced technology will open up previously unavailable opportunities in personalized medicine, early diagnosis as well as treatment and clinical monitoring.

 

 

CANCER-ID Consortium

CANCER-ID consortium

CANCER-ID Workpackages

CANCER-ID Work Plan

EUROPA - NEWS

News from the European Comission

What's new in Health and Life Sciences? Click here for news from the European Commission.

Search
Top
Home
Menu

EU logo
imi Logo
efpia Logo

News Section

Hands-on courses provided by our member TATAA Read more

Social Media

LinkedIn Cancer-ID